Understand How The Systemic Aspergillosis And Systemic Candidiasis Market Is Poised To Grow Through 2023-2032
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
As per The Business Research Company’s Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2023, the systemic aspergillosis and systemic candidiasis market is expected to show significant growth in the forecast period.
Key insights from the systemic aspergillosis and systemic candidiasis market forecast include:
- Market Size
The global systemic aspergillosis and systemic candidiasis market is projected to increase from $6.24 billion in 2022 to $6.57 billion in 2023, with a 5.2% CAGR. It is anticipated to reach $7.81 billion in 2027 at a 4.4% CAGR.
- Major Driver
The rising incidence of fungal diseases is set to drive the growth of the systemic aspergillosis and systemic candidiasis market. Fungal diseases, caused by fungi, can affect various body parts, leading to diverse symptoms and complications, including cutaneous, respiratory, and systemic infections. These conditions are managed with antifungal medications like oral azoles, voriconazole, and liposomal amphotericin B. For instance, in March 2023, the Centers for Disease Control and Prevention reported an increase in clinical cases of Candida auris, an emerging fungus, from 476 in 2019 to 1,471 in 2021 in the US. Screening cases also tripled from 2020 to 2021, reaching 4,041. Hence, the upsurge in fungal disease cases propels the systemic aspergillosis and systemic candidiasis market.
View More On The Systemic Aspergillosis And Systemic Candidiasis Market Report 2023 – https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report
- Key Trend
Innovative product development is a leading trend in the systemic aspergillosis and systemic candidiasis markets. Major companies in these markets are committed to creating inventive products to maintain their market positions. In October 2021, Intas Pharmaceuticals Limited, an India-based pharmaceutical company, introduced the world’s first Super Bioavailable Itraconazole-SB 100mg, marketed under the brand name Itaspor-SB Forte/Subawin. This medication reduces dosing frequency and can be taken with or without food, simply with water, addressing compliance issues associated with conventional Itraconazole treatments for fungal infections.
- Largest Region
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2022.
- Major Players
Major players in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., NovaDigm Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, and N8 Medical LLC.
Request A Sample Of The Global Systemic Aspergillosis And Systemic Candidiasis Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12148&type=smp
Key Systemic Aspergillosis And Systemic Candidiasis Market Segments
The global systemic aspergillosis and systemic candidiasis market is segmented –
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users
The Systemic Aspergillosis And Systemic Candidiasis Global Market Report 2023 provides an in-depth analysis on the systemic aspergillosis and systemic candidiasis market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the systemic aspergillosis and systemic candidiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
View More Related Reports –
Systemic Lupus Erythematosus Treatment Global Market Report 2023
Vaginitis Therapeutics Global Market Report 2023
Antifungals Global Market Report 2023
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
